Rexulti (Brexpiprazole), is an atypical antipsychotic that was jointly developed by pharmaceutical companies Otsuka and Lundbeck. In 2015, the FDA approved Rexulti for the treatment of schizophrenia and major depressive disorder (as an adjunct). Rexulti functions as a “serotonin-dopamine activity modulator” (SDAM) and is intended to be a superior successor to the antipsychotic Abilify (Aripiprazole) …
Rexulti (Brexpiprazole), is an atypical antipsychotic approved by the FDA for the treatment of schizophrenia and major depressive disorder (as an adjunct). The drug was engineered via collaboration between pharmaceutical companies Otsuka and Lundbeck and is considered the successor to Abilify (aripiprazole), a formerly top-selling antipsychotic medication with an expired patent. Although Rexulti is marketed …
Seroquel (Quetiapine) is an atypical antipsychotic engineered in the early 1990s by the pharmaceutical company AstraZeneca. It was first approved by the FDA in 1997 for the treatment of schizophrenia, and was sequentially approved by the FDA in 2004 for the management of bipolar mania. Seroquel would also receive subsequent FDA approval in 2009 as …
Seroquel (Quetiapine) is a medication that was developed by AstraZeneca from 1992 through 1996. It received FDA approval in 1997 for the treatment of schizophrenia, and has since received approval to treat both acute mania and depressive phases of bipolar disorder. The drug is classified as an atypical, second-generation antipsychotic and exerts pharmacological effects via …
Abilify (Aripiprazole) is a medication that was developed by Otsuka Pharmaceuticals and approved by the FDA in 2002 for the treatment of schizophrenia. Approximately 2 years thereafter (in 2004) it was approved for the treatment of acute mania and mixed episodes associated with bipolar disorder. By 2007, it had attained approval for the treatment of …
Vraylar (Cariprazine) was approved by the FDA on September 17, 2015 for the treatment of schizophrenia and mania associated with bipolar disorder. In clinical trials, the drug was referenced as “RGH-188” – containing Cariprazine as the primary active ingredient. The drug had completed Phase III clinical trials in 2012, and was pending FDA approval for …
Bipolar disorder is a condition characterized by cyclical mood swings, transitioning from depression to mania (or hypomania). For a period of time, an individual with bipolar disorder will experience debilitating bouts of depression – and often unexpectedly, their entire neurophysiology will shift to facilitate a state of mania (elevated mood). Diagnostically, there are multiple types …